Lone Star Bio
Filter News
Found 12,595 articles
-
Moleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial
8/20/2019
The trial will take place at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta.
-
CirrusMD, GreatCall, Livongo Health, Philips, and UnitedHealthcare to Keynote Connected Health Summit
8/19/2019
The keynotes will address how technology is meeting the changing healthcare needs in the consumer and commercial markets.
-
Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs
8/15/2019
Dr. Agopyan joins Marker from Kite Pharma, a subsidiary of Gilead Sciences, where she served as Director of Regulatory Affairs, Global Regulatory Lead.
-
Loopback Analytics Chosen to Support Credena Health Specialty Pharmacy to Improve Patient Outcomes
8/15/2019
Providence Health & Services, to advance specialty pharmacy services at the Providence Health affiliates in Washington, Montana and Oregon.
-
Texas State Optical, Inc. Elects New Board Leadership
8/15/2019
Elected to Board of Directors Chairman position is Dr. Reid Robertson, Past Committee chairman of the Nomination Committee of Allen, Texas.
-
RES Makes Inc. 5000 for Ninth Consecutive Year
8/15/2019
Growing Scale of Projects Pushes RES to Rank #3,331
-
Carbon nanotubes are a type of nanomaterials made up of a two-dimensional lattice of carbon atoms. Researchers at Texas Heart Institute recently used bio-compatible nanotubes invented at Rice University to restore electrical function to damaged hearts.
-
TSAOG Orthopaedics Implements Radix Health's DASH® Patient Access Software to Expand Digital Front Door
8/14/2019
TSAOG Orthopaedics elected to implement DASHself to increase patient access by enabling patients to book their own appointments online.
-
Moleculin Announces Completion of Lymphoma Trial Enrollment
8/13/2019
Announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment.
-
The deal has a flexible framework, which will allow for a variety of projects at different stages of development over several years.
-
Apollo Endosurgery, Inc. Announces Closing of $20 Million Private Placement of Convertible Debentures
8/12/2019
Interest on the debentures is payable semi-annually in common stock, or in kind in certain situations, at a rate per annum of 6.0%.
-
The pooled data results came five months after the FDA rejected Zynquista following a split advisory committee vote.
-
CynergisTek Sees Increased Demand for Medical Device Security Services in First Year of Deployment
8/8/2019
Leading Cybersecurity Firm Significantly Grows Client Roster Through New and Expanded Client Contracts To Address Evolving Security Needs
-
McKesson Playing Pivotal Role in Phase II of Friends of Cancer Research Real-World Evidence Initiative
8/8/2019
Pivotal study to inform framework for how to use RWE to support regulatory and reimbursement decisions
-
Axxess Partners with PlayMaker Health to Deliver Referral and Growth Data Intelligence for Home Health and Hospice Clients
8/8/2019
Axxess to Make PlayMaker Health Data Available for More than 2,000 Clients
-
Although anti-retroviral therapies have come a long way in turning HIV into being treated like a chronic, manageable disease, researchers are still attempting to find something that might be considered a cure, which would completely eradicate the virus. Researchers from University of Texas Medica...
-
Parks Associates: 43% of US Broadband Households Plan to Purchase a Smart Home Device in 2019
8/7/2019
Research firm announces topics for CONNECTIONS™ Summit at CES: Smart Home Business Models and Strategies
-
Young Blood Plasma Parkinson's Disease Investigation Six-Month Results Show Dramatic Improvements In Motor Symptoms and Mentation, Behavior and Mood
8/7/2019
Six-month results of their randomized controlled investigation of intravenously administering NuPlasma® young blood plasma into eighteen Parkinson's disease patients
-
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
8/7/2019
Conference call to take place Tuesday, August 13, 2019 at 8:30 am Eastern time
-
Marker Therapeutics Appoints Steve Elms to its Board of Directors
8/6/2019
Mr. Elms has held numerous leadership roles in the healthcare sector.